Here’s what you should know:
1. The company wants to hit an adjusted operating margin of 25 percent in 2017 and 28 percent by 2020.
2. The company also said it wants “consistent” earnings per share growth between 6 percent and 8 percent through 2020.
3. To accomplish this, Boston Scientific wants to reduce its holdings in low-growth markets, while adding to its lines in high-growth adjacent markets. The company plans to add $14 billion to addressable markets by 2020.
4. Boston Scientific Michael Mahoney said, “We are committed to fulfilling our promises to patients, customers and shareholders by delivering a comprehensive, innovative and cost effective portfolio of products and solutions within our served markets while also expanding into new, high growth adjacent markets.”
More articles on transactions/valuations:
ASC owners challenge Georgia’s CON law in state Supreme Court: 4 things to know
5 shifting trends affecting ASC, physician practice valuation
St. Anthony Summit Medical Center to offer outpatient, specialty care — 3 insights
